Investigational Drug Information for Mapracorat
✉ Email this page to a colleague
What is the drug development status for Mapracorat?
Mapracorat is an investigational drug.
There have been 12 clinical trials for Mapracorat.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2011.
The most common disease conditions in clinical trials are Inflammation, Cataract, and Eczema. The leading clinical trial sponsors are Bausch & Lomb Incorporated, Bayer, and [disabled in preview].
Summary for Mapracorat
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 67 |
| WIPO Patent Applications | 40 |
| Japanese Patent Applications | 8 |
| Clinical Trial Progress | Phase 3 (2011-02-01) |
| Vendors | 34 |
Recent Clinical Trials for Mapracorat
| Title | Sponsor | Phase |
|---|---|---|
| 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat | Bayer | Phase 1 |
| Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days | Bausch & Lomb Incorporated | Phase 1 |
| Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery | Bausch & Lomb Incorporated | Phase 3 |
Clinical Trial Summary for Mapracorat
Top disease conditions for Mapracorat
Top clinical trial sponsors for Mapracorat
US Patents for Mapracorat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
